Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06626633
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-01
Brief Title:
2321GCCC CRD3874-SI in Patients with Relapsedrefractory AML
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Phase 1 Clinical Trial of the STING Agonist CRD3874-SI in Patients with Relapsedrefractory Acute Myeloid Leukemia
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical research study is being done to answer questions about how to treat cancer
To clear cancer cells from the body the immune system needs the action of proteins called Type 1 interferons The protein STING for STimulator of INterferon Genes stimulates the body to make Type 1 interferons Type 1 interferons activate key molecules in cancer immunity to kill cancer cells
CRD3874 is a synthetic drug that activates STING and STING stimulates the immune system to kill cancer cells In experiments on blood from humans CRD3874 makes blood cells produce molecules responsible for anti-cancer activity CRD3874 was tested in mice with cancers including leukemia head and neck cancer lung cancer pancreatic cancer and sarcoma In these mice CRD3874 made tumors shrink or disappear and some mice developed long-lasting immunity against cancer Also when CRD3874 was given with other anti-cancer treatments it increased their anti-cancer effects
To clear cancer cells from the body the immune system needs the action of proteins called Type 1 interferons The protein STING for STimulator of INterferon Genes stimulates the body to make Type 1 interferons Type 1 interferons activate key molecules in cancer immunity to kill cancer cells
CRD3874 is a synthetic drug that activates STING and STING stimulates the immune system to kill cancer cells In experiments on blood from humans CRD3874 makes blood cells produce molecules responsible for anti-cancer activity CRD3874 was tested in mice with cancers including leukemia head and neck cancer lung cancer pancreatic cancer and sarcoma In these mice CRD3874 made tumors shrink or disappear and some mice developed long-lasting immunity against cancer Also when CRD3874 was given with other anti-cancer treatments it increased their anti-cancer effects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None